ConvaTec Group (LON:CTEC – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Jefferies Financial Group in a note issued to investors on Wednesday,London Stock Exchange reports. They currently have a GBX 300 price objective on the stock. Jefferies Financial Group’s target price points to a potential upside of 32.98% from the stock’s previous close.
Several other research analysts have also issued reports on CTEC. JPMorgan Chase & Co. lowered their target price on ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating for the company in a research report on Friday, May 22nd. Royal Bank Of Canada reiterated an “outperform” rating and issued a GBX 315 price target on shares of ConvaTec Group in a research report on Monday. Berenberg Bank reissued a “buy” rating and issued a GBX 340 price target on shares of ConvaTec Group in a research note on Tuesday, April 21st. Citigroup decreased their price target on ConvaTec Group from GBX 250 to GBX 230 and set a “neutral” rating for the company in a research note on Monday, May 18th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 315 price objective on shares of ConvaTec Group in a research report on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 306.
View Our Latest Stock Report on CTEC
ConvaTec Group Trading Down 1.7%
Insider Buying and Selling at ConvaTec Group
In other news, insider Jonny Mason acquired 50,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was bought at an average cost of GBX 201 per share, for a total transaction of £100,500. 0.98% of the stock is currently owned by company insiders.
ConvaTec Group Company Profile
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Further Reading
- Five stocks we like better than ConvaTec Group
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
- 3 Stocks Taking Very Different Routes Through the Summer Rally
- Is ADM’s Rally Getting Ahead of Its Policy Tailwind?
- CoreWeave Powers Up: The Asia Infrastructure Grab
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
